Fig. 6.

Eradication of 4T1-12B tumors upon gemcitabine treatment in KO mice provides partial protection against 4T1 tumor growth. a KO mice that had previously rejected 4T1-12B tumors upon gemcitabine treatment and naïve KO mice controls were challenged with 5 × 10⁴ 4T1 cells. Tumor volume was measured weekly, and b final tumor weight was quantitated after 4 weeks. c Splenocytes from KO naïve or re-challenged mice [1° vs. 2° tumor (Tu) injection] were cultured for 7 days with IL-2 and AH1 peptides in vitro prior to staining with AH1-tetramers. Data presented as mean ± standard error. The presented data were either pooled from two to three experiments, or represent two or more independent experiments with similar results. *P < 0.05; **P < 0.01; ***P < 0.001